Indications and Mechanism of Action of Brigatinib

Indications and Mechanism of Action of Brigatinib

Brigatinib is used to treat adult patients with advanced non-small cell lung cancer, especially those whose tumors have a genetic defect in anaplastic lymphoma kinase (ALK). This genetic defect produces an abnormal kinase protein that stimulates cancer cells to grow and spread continuously. Brigatinib is a kinase inhibitor that effectively blocks the action of this abnormal protein, thereby slowing the growth and metastasis of lung cancer. This medication must be used under clear diagnosis and guidance of a physician and is not recommended for individuals under 18 years of age due to lack of corresponding clinical trial data.

Contraindications and Urgent Warnings for Brigatinib

Brigatinib is contraindicated in the following situations: hypersensitivity to brigatinib or any other ingredients of this product (such as lactose monohydrate, microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide, magnesium stearate, talc, polyethylene glycol, polyvinyl alcohol, titanium dioxide, etc.). Before taking the medication, you must inform your doctor if you have any lung or breathing problems, as serious pulmonary adverse reactions may occur within the first 7 days of treatment, with symptoms resembling worsening lung cancer (e.g., difficulty breathing, shortness of breath, chest pain, cough, fever). In addition, you should inform your doctor in advance if you have high blood pressure, slow pulse, visual disturbances, unexplained muscle pain or weakness, upper abdominal pain (which may indicate pancreatitis), right-sided abdominal pain with yellowing of the skin and eyes (suggesting liver injury), hyperglycemia, photosensitivity, or kidney disease, so that the treatment plan can be adjusted or the medication temporarily withheld.

Key Monitoring Parameters During Brigatinib Treatment

During treatment with brigatinib, your doctor will require you to undergo regular blood tests and physical assessments to promptly detect and manage potential adverse reactions. The most important monitoring parameters include: blood pressure (as this drug may cause hypertension, requiring regular measurement and antihypertensive medications if necessary); heart rate and electrocardiogram (due to possible bradycardia or QT prolongation, presenting as slow pulse, dizziness, palpitations); blood creatine kinase levels (elevation indicates possible muscle injury, such as damage to cardiac or skeletal muscle); pancreatic enzyme (amylase and lipase) levels (elevation suggests risk of pancreatitis); liver function indicators (aspartate aminotransferase, alanine aminotransferase, bilirubin, etc.; elevation indicates liver cell injury); kidney function indicators (creatinine, blood urea nitrogen); blood glucose levels (hyperglycemia may occur); and complete blood count including red blood cells, white blood cells, and platelets (indicating anemia, infection risk, and bleeding tendency, respectively). In addition, special attention should be paid to pulmonary symptoms within the first 7 days of treatment, as severe pulmonary inflammation often occurs during this period. Please complete all follow-up examinations as instructed by your doctor, and never interrupt or adjust the medication on your own.